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Background: Diabetic patients present with an accelerated atherosclerotic process and an increased risk for future
cardiovascular events. In addition to the risk imposed by the disease itself, pharmacological treatment adds also a
sizable risk, especially if certain classes of antidiabetic drugs are employed. Animal evidence indicates that
dipeptidyl peptidase-4 inhibitors have anti-atherosclerotic effects, yet clinical data are scarcely available.
Design: We plan to prospectively investigate the effects of dipeptidyl peptidase-4 inhibition with vildagliptin on a
number of atherothrombotic markers and adipokines in patients with proven atherosclerosis and type 2 diabetes.
The selected markers are: interleukin-6, high sensitivity C reactive protein, interleukin 1-beta, total adiponectin levels,
matrix metallo-proteinase 9 and platelet reactivity testing. Sixty eligible patients will be randomized in a 2:1 ratio to
vildagliptin/metformin or metformin only treatment, for a 3-month duration treatment. Blood sampling for the
proposed investigations will be taken at enrollment and immediately after completion of the study period.
Discussion: Demonstrating antiatherothrombotic properties of dipeptidyl peptidase-4 inhibitors on proven markers
is of substantial clinical significance. Coupled with their proven good safety profile these findings could translate
into a significant clinical benefit.
Keywords: Type 2 diabetes, Vildagliptin, Metformin, Atherosclerosis, Inflammation, Interleukin-6, TNF,
Atherothrombosis, Adiponectin, MMP-9, hs-CRPBackground
Patients with ischemic heart disease and diabetes are at a
particularly high risk for the recurrence of cardiovascular
events. Conversely, certain classes of oral antidiabetic
medications have been shown to cause hypoglycemia as
well as adverse cardiovascular effects [1-3]. Diabetes
induces complex vascular changes, promoting accelerated
atherosclerosis and hypercoagulability, as can be assessed
indirectly by a number of markers. Principal perturbations
include endothelial dysfunction, increased inflammatory
plaque infiltration, adhesion molecule over-expression and* Correspondence: Robert.Klemper@sheba.health.gov.il
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distribution, and reproduction in any mediumadverse effects of circulating fatty acids and advanced gly-
cosylation end products.
Animal studies have suggested numerous beneficial
antiatherosclerotic changes of dipeptidyl peptidase-4 inhi-
bitors (DPP4i), well beyond the effects on blood glucose
alone [4,5]. Additionally, antiremodeling effects are pro-
posed [6]. However, this feature has not been established
in a clinical setting. Concomitant treatment with a DPP4i
and metformin may offer an attractive glycemic reduction
modality with synergistic mechanism of action while exert-
ing additional vascular protective benefits. Reduction of in-
flammatory marker levels is of great clinical importance
and has been shown to correlate with reduction in signifi-
cant clinical events. Therefore, in the present study we plan
to focus on possible anti inflammatory and atherothrombo-
tic protective effects of DPP4i in a clinical setting.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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chosen in order to correctly represent alterations in:
inflammation (hs-CRP), risk of atherosclerotic plaque
rupture and matrix turnover (MMP-9), and platelet re-
activity (aggregability tests). These markers are further
detailed:
Interleukin 6 (IL-6)
This established inflammatory marker has been shown
to be increased in individuals with coronary artery
disease [7,8]. Furthermore, diabetes has been referred
to as a chronic inflammatory state. Therefore, a reduc-
tion in inflammatory markers in this high-risk popula-
tion is likely to correlate with a corresponding
reduction in the risk for atherothrombotic events.
High sensitivity C-reactive protein (hs-CRP)
Marker of inflammation with a strong correlation with
cardiovascular events even in normolipemic popula-
tion [9]. Reduction of hs-CRP has been demonstrated
with vildagliptin-pioglitazone combination, but data
from patients with cardiovascular disease and vilda-
gliptin-metformin combination are lacking [10].
Platelet reactivity testing
Platelets are hyper-reactive in diabetic patients, and
this heightened activity is closely linked to vascular
events [11,12]. Perturbations in both structure and
function have been described [13,14]. Reduction in re-
activity is a viable surrogate of reduced thrombogenic
milieu [15]. However, currently there are no human
data on the effects of DPP4i on platelet function. We
hypothesize that a combined vildagliptin-metformin
therapy will be associated with a greater reduction in
platelet reactivity as compared with metformin
monotherapy.
Adiponectin
Hormone with regulatory metabolic function secreted
from the adipose tissue. Reduced levels of adiponectin
were shown to be associated with obesity, metabolic
syndrome, and diabetes, and to promote the athero-
sclerotic process [16-18]. Higher levels have been
found to be protective [18,19]. Reduction in adiponec-
tin levels induced by fatty diet has recently been shown
to be corrected by DPP4i in mice [4], yet the effect in
diabetic humans is unknown.
Matrix metallo-proteinases 9 (MMP-9)
The MMPs are a large family of zinc-dependent, extra-cel-
lularly acting endo-peptidases. Substrates of MMPs are pro-
teins of the extracellular matrix and adhesion proteins.
Patients with coronary artery disease were recently shown
to have increased levels of MMP-9 [20]. A higher MMP-9level was also shown to correlate with coronary artery ecta-
sia [21], and to predict increased mortality in patients with
coronary artery disease [22]. Accordingly, we hypothesize
that treatment with combined vildagliptin-metformin ther-
apy will be associated with significantly greater reductions
in MMP-9 levels as compared with metformin
monotherapy.
The effect of DPP4i on the above-mentioned para-
meters has not been studied in humans. Accordingly,
the demonstration of significant improvements in mar-
kers of atherothrombosis and inflammation in high-
risk diabetic patients is of great clinical importance
and novelty that may be employed for the reduction of
major cardiovascular events in this population.
Study design
Study purpose
To demonstrate that combined vildagliptin-metformin
therapy is associated with clinically significant reductions in
biological markers of inflammation, pro-thrombogenicity,
and atherosclerosis as compared to metformin mono-
therapy in a population of diabetic patients with coronary
artery disease who undergo cardiac rehabilitation.
The prespecified established biological markers of in-
flammation, pro-thrombogenicity, and atherosclerosis
will include: interleukin-6 (IL-6 – primary biological
marker), hs-CRP, platelet reactivity testing, MMP-9,
interleukin 1 beta (IL-1 beta) and adiponectin levels.
Findings from this analysis will demonstrate the
pleiotropic effects of DPP4i in a clinical setting, in
addition to its established antiglycemic effects.
Specific aims
2.1. Primary Aim: Demonstration of a significant (≥
20%) reduction in the serum levels of interleukin 6
(IL-6)
2.2. Secondary Aims:Improvement in other markers of atherothrombosis
and inflammation:




Matrix metallo-proteinase 9 (MMP-9)
Additional exploratory markers including: IL-1
alpha, IL-17, TNF-alpha, MCP-1, monocyte
subsets by FACS
Safety from hypoglycemic events
Reduction in glycosylated hemoglobin (Hb
A1c)
Weight reduction
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Rationale of study design
The study is designed as a single-center, randomized,
non-blinded, clinical trial to provide evidence on the
effects of vildagliptin on key biomarkers of athero-
thrombosis and inflammation. We plan to prospect-
ively enroll 60 patients with proven coronary artery
disease and randomize them in a 2:1 ratio to either vil-
dagliptin-metformin therapy (n = 40) or metformin
therapy (n = 20). Study design and flow are presented
in Figure 1.
Rationale of dose, duration of treatment
Vildagliptin-metformin combination is approved by
the ministries of health and is commercially available
in Israel and Europe. It has been shown to induce sig-
nificantly less hypoglycemic events and therefore lower
sympathetic activation detrimental for cardiac patients.
The effects of vildagliptin-metformin combination vs.
metformin monotherapy will be assessed 3-months
after initiation of therapy. The short duration of the
study and frequent follow-up visits with weekly inter-
action with study personnel will ensure the safe con-
duct of this trial and improve participant adherence.
The 3-month duration has been shown in previousFigure 1 Figure 1 Study design and flow.marker centered studies to be sufficiently long to in-
duce the anti-atherothrombotic and anti-atheroscler-
otic changes. Metformin has been chosen for the
comparison group, for the following reasons: 1) the
drug was shown to be one of the most efficacious
therapeutic options available [23,24]; 2) the clinical ex-
perience with the drug is extensive; and 3) it is a com-
ponent of the comparison group vildagliptin-
metformin combination.Study population
 Participants eligible for this trial will include male
and non-child-bearing potential female patients age
21 years and older who have (a) documented
coronary artery disease> 30 day; and (b) evidence of
suboptimal type II diabetes control on the basis of
Hb A1c ≥7.0%, despite the use of oral antidiabetic
monotherapy. Standard of care secondary
prevention for coronary artery disease background
therapy will include, but will not be limited to, lipid
lowering, antihypertensive, beta blockers, and
antiplatelet therapy, as appropriate and in
accordance to current guidelines.1
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 Type 2 diabetes mellitus on oral mono-therapy or
diet only treatment
 Stable documented ischemic heart disease (>30 days
post AMI, CABG or PCI)
 Suboptimal Hb A1c as defined ≥7.0%
 Age> 21
 Life expectancy >1 year
Exclusion criteria
 Significant renal impairment (creatinine ≥1.4 mg\dL
females or ≥1.5 mg\dL males)
 Planned coronary intervention or planed surgical
intervention (PCI or CABG)
 Planned surgical intervention
 Recent (<30 day) acute coronary syndrome (ACS)
 Hypersensitivity to either of the study drug
components
 History of lactic acidosis
 Type I diabetes
 Current Hb A1c >9%
 Current Insulin treatment
 Active treatment with GLP-1 or other DPP4i
medication
 Hepatic impairment or ALT\AST elevations beyond
X2 upper normal limit or known hepatic failure
 Inability to comply with study protocol
 Active malignancy other than basal cell carcinoma
 Clinically advanced congestive heart failure - NYHA
III-IV
 Severe left ventricular dysfunction (LVEF< 30%)
with NYHA II or any NYHA class with documented
recent heart failure decompensation (<3 months)
 Severe stable cardiac angina CCS III – IV or
Unstable angina
 Chronic inflammation (i.e. inflammatory bowel
disease, lupus, inflammatory arthritis, rheumatoid
arthritis) or chronic infection (i.e. chronic diabetic
foot infection)
 Pregnancy, lactation or child-bearing potential
Baseline clinical evaluation
At baseline patients will undergo detailed assessment in-
cluding: 1) focused medical history, past cardiovascular
events and key clinical findings, 2) body mass index (BMI)
measurements, 3) physical examination and medication
history. Based on current medication patients will be
initiate a wash-out period of 2-weeks as described below.
Prior antidiabetic medication washout
Eligible patients (Hb A1c ≥7% and ≤ 9%) who receive
current anti-diabetic monotherapy (not includingmetformin or a DPP4i) who consent to participate in
the study will initially receive substituted antidiabetic
treatment with metformin. Prespecified substitution of
oral antidiabetic monotherapy is permitted if clinically
reasonable and safe. A washout period of two weeks
will take place prior to randomization. During this
period, treatment with open label metformin will be
carried out with blood glucose monitored regularly.
Initial dose will be 850 mg once daily, with a dose in-
crease to a maximum of 850 mg TID stabilization to a
target of fasting glucose ≤130 mg/dL. For patients eli-
gible for the study who receive current treatment with
metformin monotherapy, a dose increase will also be
allowed to a maximum of 850 mg TID aiming for
stabilization to a target of fasting glucose ≤130 mg/dL.
Stabilization of oral anti-diabetic therapy for eligible
patients not on previous therapy
Eligible patients (HbA1C ≥7% and< 9%) not on current
antidiabetic therapy who will consent to participate on
the study will be initiated with open-label metformin
monotherapy for a period of two weeks prior to
randomization. During this period, treatment with met-
formin will be carried out with blood glucose monitored
regularly. Initial dose will be 850 mg once daily, with a
dose increase to a maximum of 850 mg TID until
stabilization to a target of fasting glucose <130 mg/dL.
Randomization
Randomization will be carried out following a 2-week
period of stabilization on metformin mono-therapy as
described above. Patients will be randomized in a 2:1 ratio
to open label treatment with vildagliptin-metformin therapy
or metformin mono-therapy. This study will be non-
blinded to patients and treating personnel. All laboratory
tests, the major study endpoints, will be performed by pro-
fessionals blinded to treatment allocation. An interim ana-
lysis will be performed after the recruiting 50% of proposed
study participants.
Treatment
The entire study group will be actively treated orally with
either metformin (control group) or metformin-vildagliptin
combination (intervention group), once or twice daily. No
placebo medication is used in this study. The study is open-
labeled. Endpoints are mostly laboratory ones, so the un-
blinded design will have a minimal effect on the validity of
the obtained results.
Treatment will be initiated as follows: (1) in the control
arm, metformin dose will be based on the treatment pre-
scribed at the end of the 2 week pre-randomization period;
and (2) in the investigational arm, metformin will be
replaced with combined metformin-vildagliptin treatment
with an initial dose of once daily. Titration to the three
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ical judgment in the control arm, while in the metformin-
vildagliptin combination, maximal dose will be twice daily.
Study patients and other treating physicians will be
asked not to alter antidiabetic medication unless there is
justifiable clinical urgency. As statin have proven anti-in-
flammatory and diverse pleotropic properties, statin type
and dose will be recommended to remain fixed during
the 3-month study period, unless otherwise clinically
indicated.
Medication titration
Study design permits, based on blood glucose measure-
ments and additional lab test if deemed necessary, modifi-
cation of the medication dose with the goal of fasting
glucose ≤ 130 mg/dl. In the control arm up-titration will be
carried out with metformin, and in the treatment arm up-
titration will be carried out with vildagliptin-metformin
combination. If control of blood glucose cannot be
achieved after maximal drug titration and there are
repeated (>3) measurements of FPG> 300 mg/dl after nu-
tritional consultation and exercise, the study investigator is
encouraged to add antidiabetic treatment according to
medical judgment and national guidelines. Deviations from
study protocol are to be recorded in detail on appropriate
eCRF. With the exception of severe exacerbations in glu-
cose homeostasis noted earlier, all effort is to be made to
maintain a stable treatment plan in coordination with the
family physician. Patient’s adherence to study medication
will be evaluated by pill-count at the follow-up visits.
Follow-up visits
All patients will be invited for monthly follow-up visits with
study coordinators. During these visits we plan to monitor
both clinical and adverse events, verify medication com-
pliance and evaluate any hypoglycemic events. Trained
medical personnel will verify the home monitoring glucose
journal. Changes in weight and in drug regiment will be
recorded. At the completion of 3-months blood will be
drawn for laboratory testing as done at baseline. Blood sam-
ples will not contain identifying information and all tests
are to be performed in a blinded fashion.
Statistical methods and power calculation
Sample size justification: We expect to show an improve-
ment (defined as >20% biomarker reduction between the
baseline and 3-month assessment) in ≥3 of the prespeci-
fied biomarkers that comprise the primary end point in at
least 50% of the patients randomized to combined vilda-
gliptin-metformin therapy and in <10% of the patients
randomized to metformin mono-therapy. The proposed
sample size is calculated to demonstrate a significant im-
provement in the intervention group compared to the
control group with at least 90% power and a two-sided 5%type 1 error. These requirements are met with a sample
size of 60 patients and a 2:1 randomization design: 40
patients in the combined vildagliptin-metformin interven-
tion group and 20 in the metformin monotherapy control
group.
Discussion
Treatment of diabetes is more than the reduction of
blood glucose [24,25]. Patients with glycosylated
hemoglobin within guidelines recommended values have
a substantial residual risk compared to the healthy popu-
lation. As atherosclerosis is the leading cause of death
and morbidity in the diabetic population, interventions
that potentially reduce this risk are of crucial import-
ance. Statins have been shown to substantially reduce
the risk of MACE in diabetic patients with pleiotropic
effects beyond the reduction of LDL [26-28]. Animal
models found intriguing antiatherosclerotic influences
that could translate into a substantial clinical benefit [4].
The design of this study serves two important roles:
first, the short duration will permit meticulous follow-
up, and adherence to protocol. Secondly, it will enhance
safety and minimally interfere with regular patient man-
agement. In order to reduce interference from concomi-
tant medication changes, especially statins, we plan to
enroll patients with a stable drug regiment that is in ac-
cordance to national guidelines. We will encourage the
managing physician to refrain from drug or dose
changes within the short study duration unless deemed
necessary. We did not deem it important to blind treat-
ment as all study end-points are laboratory ones, per-
formed on de-identified blood samples by personnel
blinded to patients data or study allocation. This open-
labeled design will also enhance patient safety. Cardio-
vascular safety of antidiabetic medication is of para-
mount importance and has been under recent FDA
scrutiny [29]. A number of hypoglycemic drugs, espe-
cially sulfonylureas, have been associated with significant
hypoglycemia and adverse events induced by sympa-
thetic activation. Activation of the sympathetic system
has numerous implications, including surges of heart
rate, blood pressure but also proinflammatory and pro-
coagulant effects. This partially explains the increased
cardiovascular adverse events noted with these drugs.
DPP4i have a good safety profile [30,31]. A vildagliptin-
metformin combination has the potential to reduce the
rate of hypoglycemic events. Notably, the anti-inflamma-
tory effect of DPP4i may be partially explained by lack of
repetitive sympathetic activations. These hypothesized
protective effects will be evaluated in the clinical setting
of the proposed study.
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